We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
Read MoreHide Full Article
Key Takeaways
Dorian LPG (+26.4%) and FS Bancorp (+8.2%) outperformed the S&P 500 since June upgrades.
Pharming Group (+49%) and Lumentum (+45.5%) surged after July upgrades to Outperform.
Intellia Therapeutics (+58.6%) and CBRE (+30.2%) beat the S&P 500 +8.8% gain over 12 weeks.
Last Friday, the three most widely followed benchmark indexes closed a losing week. The Dow Jones Industrial Average, the Nasdaq Composite and the S&P 500 lost 0.2%, 0.2% and 0.1%, respectively. However, for the month, the Dow, the S&P 500 and Nasdaq notched up gains of 3.2%, 1.9% and 1.6%, respectively.
Last week, trade was held back by a combination of profit-taking and growing inflation concerns. Despite earlier record highs driven by strong Q2 GDP data, investors dialed back positions ahead of a key PCE inflation report, which signaled persistent price pressures. Fed signals at Jackson Hole in the week prior had hinted at possible rate cuts, but that optimism was offset by stubborn inflation metrics and mixed corporate earnings
Broader sentiment was dampened by lingering geopolitical tensions, particularly U.S.-China and U.S.-India trade frictions and uncertainty over energy markets amid the Middle East unrest.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Dorian LPG and FS Bancorp Surge Following Zacks Rank Upgrade
Shares of Dorian LPG Ltd. (LPG - Free Report) have gained 26.4% (versus the S&P 500’s 6.2% increase) since it was upgraded to a Zacks Rank #1 (Strong Buy) on June 26.
Another stock, FS Bancorp, Inc. (FSBW - Free Report) , which was upgraded to a Rank #2 (Buy) on June 27, has returned 8.2% (versus the S&P 500’s 5.4% increase) since then.
A hypothetical portfolio of Zacks Rank # 1 (Strong Buy) stocks returned +1.47% in 2025 (through August 4th) vs. +5.60% for the S&P 500 index and +6.77% for the equal-weight version of the index.
This portfolio returned +22.4% in 2024, vs. +28% for the S&P 500 index and +19.9% for the equal-weight version of the S&P 500 index.
This hypothetical portfolio returned +20.65% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 12 percentage points since 1988 (through August 4th, 2025, the Zacks # 1 Rank stocks generated an annualized average return of +23.6% vs. +11.3% for the S&P 500 index).
Zacks Recommendation Upgrades Pharming Group and Lumentum
Shares of Pharming Group N.V. (PHAR - Free Report) and Lumentum Holdings Inc. (LITE - Free Report) have surged 49% (versus the S&P 500’s 3.1% rise) and 45.5% (versus the S&P 500’s 4% rise), since their Zacks Recommendation was upgraded to Outperform on July 11th and July 9th, respectively.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Intellia Therapeutics, CBRE Shoot Up
Shares of Intellia Therapeutics, Inc. (NTLA - Free Report) , which belongs to the Zacks Focus List, have gained 58.6% over the past 12 weeks. The stock was added to the Focus List on March 7, 2023. Another Focus-List holding, CBRE Group, Inc. (CBRE - Free Report) , which was added to the portfolio on March 13, 2017, has returned 30.2% over the past 12 weeks. The S&P 500 has advanced 8.8% over this period.
The 50-stock Focus List portfolio returned 10.91% in 2025 (through July 31st, 2025) vs. +8.59% for the S&P 500 index and +5.84% for the equal-weight version of the index.
The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index. The portfolio had returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio returned -15.2% vs. the S&P 500 index’s -17.96%.
The portfolio leads the broader market over the preceding one, three, five and ‘since 2004’ periods. These annualized return comparisons are: +17.71% for the Focus List vs. +16.35% for the index over the one-year period, +19.21% vs. +17.101% over the 3-year period, +16.98% vs. +15.88% over the 5-year period, and +11.9% vs. +10.51% since 2004.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Oracle Corporation (ORCL - Free Report) , a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 35.8% over the past 12 weeks. Thermo Fisher Scientific Inc. (TMO - Free Report) has followed Oracle with 24.3% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned +3.20% in the first quarter of 2025 vs. the S&P 500 index’s -4.30% decline (SPY ETF).
For the year 2024, the portfolio returned +16.26% vs. +24.89% for the S&P 500 index (SPY ETF).
In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks Tractor Supply and Fastenal Outperform Peers
Tractor Supply Company (TSCO - Free Report) , which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 29% over the past 12 weeks. Another ECDP stock, Fastenal Company (FAST - Free Report) , has climbed 21.4% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -3.17% in 2025 Q2 vs. the S&P 500 index’s +10.94% gain and the Dividend Aristocrats ETF’s (NOBL) -0.09% return. Year-to-date (through June 30th), the portfolio returned +2.38% vs. +2.18% gain for the Dividend Aristocrat ETF.
For the full-year 2024, the portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL.
The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
MasTec, Inc. (MTZ - Free Report) , from the Zacks Top 10 Stocks for 2025, has jumped 33.5% year to date compared with the S&P 500 Index’s 10.1% increase.
The Top 10 portfolio returned +11.8% this year (through the end of June 2025) vs. +6.2% for the S&P 500 index and +4.8% for the equal-weight version of the index.
The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index. The portfolio had returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.
Since 2012, the Top 10 portfolio has produced a cumulative return of +2,220.4% through the end of July 2025 vs. +517.8% for the S&P 500 index and +378% for the equal-weight version of the index. The portfolio has produced an average return of +26.1% in the period 2012 through July 31, 2025, vs. +14.4% for the S&P 500 index and +12.2% for the equal-weight version of the index.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
Key Takeaways
Last Friday, the three most widely followed benchmark indexes closed a losing week. The Dow Jones Industrial Average, the Nasdaq Composite and the S&P 500 lost 0.2%, 0.2% and 0.1%, respectively. However, for the month, the Dow, the S&P 500 and Nasdaq notched up gains of 3.2%, 1.9% and 1.6%, respectively.
Last week, trade was held back by a combination of profit-taking and growing inflation concerns. Despite earlier record highs driven by strong Q2 GDP data, investors dialed back positions ahead of a key PCE inflation report, which signaled persistent price pressures. Fed signals at Jackson Hole in the week prior had hinted at possible rate cuts, but that optimism was offset by stubborn inflation metrics and mixed corporate earnings
Broader sentiment was dampened by lingering geopolitical tensions, particularly U.S.-China and U.S.-India trade frictions and uncertainty over energy markets amid the Middle East unrest.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Dorian LPG and FS Bancorp Surge Following Zacks Rank Upgrade
Shares of Dorian LPG Ltd. (LPG - Free Report) have gained 26.4% (versus the S&P 500’s 6.2% increase) since it was upgraded to a Zacks Rank #1 (Strong Buy) on June 26.
Another stock, FS Bancorp, Inc. (FSBW - Free Report) , which was upgraded to a Rank #2 (Buy) on June 27, has returned 8.2% (versus the S&P 500’s 5.4% increase) since then.
A hypothetical portfolio of Zacks Rank # 1 (Strong Buy) stocks returned +1.47% in 2025 (through August 4th) vs. +5.60% for the S&P 500 index and +6.77% for the equal-weight version of the index.
This portfolio returned +22.4% in 2024, vs. +28% for the S&P 500 index and +19.9% for the equal-weight version of the S&P 500 index.
This hypothetical portfolio returned +20.65% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 12 percentage points since 1988 (through August 4th, 2025, the Zacks # 1 Rank stocks generated an annualized average return of +23.6% vs. +11.3% for the S&P 500 index).
You can see the complete list of today’s Zacks Rank #1 stocks here >>>
Check Dorian LPG’s historical EPS and Sales here>>>
Check FS Bancorp’s historical EPS and Sales here>>>
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades Pharming Group and Lumentum
Shares of Pharming Group N.V. (PHAR - Free Report) and Lumentum Holdings Inc. (LITE - Free Report) have surged 49% (versus the S&P 500’s 3.1% rise) and 45.5% (versus the S&P 500’s 4% rise), since their Zacks Recommendation was upgraded to Outperform on July 11th and July 9th, respectively.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Intellia Therapeutics, CBRE Shoot Up
Shares of Intellia Therapeutics, Inc. (NTLA - Free Report) , which belongs to the Zacks Focus List, have gained 58.6% over the past 12 weeks. The stock was added to the Focus List on March 7, 2023. Another Focus-List holding, CBRE Group, Inc. (CBRE - Free Report) , which was added to the portfolio on March 13, 2017, has returned 30.2% over the past 12 weeks. The S&P 500 has advanced 8.8% over this period.
The 50-stock Focus List portfolio returned 10.91% in 2025 (through July 31st, 2025) vs. +8.59% for the S&P 500 index and +5.84% for the equal-weight version of the index.
The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index. The portfolio had returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio returned -15.2% vs. the S&P 500 index’s -17.96%.
The portfolio leads the broader market over the preceding one, three, five and ‘since 2004’ periods. These annualized return comparisons are: +17.71% for the Focus List vs. +16.35% for the index over the one-year period, +19.21% vs. +17.101% over the 3-year period, +16.98% vs. +15.88% over the 5-year period, and +11.9% vs. +10.51% since 2004.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Oracle & Thermo Fisher Scientific Make Significant Gains
Oracle Corporation (ORCL - Free Report) , a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 35.8% over the past 12 weeks. Thermo Fisher Scientific Inc. (TMO - Free Report) has followed Oracle with 24.3% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned +3.20% in the first quarter of 2025 vs. the S&P 500 index’s -4.30% decline (SPY ETF).
For the year 2024, the portfolio returned +16.26% vs. +24.89% for the S&P 500 index (SPY ETF).
In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks Tractor Supply and Fastenal Outperform Peers
Tractor Supply Company (TSCO - Free Report) , which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 29% over the past 12 weeks. Another ECDP stock, Fastenal Company (FAST - Free Report) , has climbed 21.4% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
Check Tractor Supply’s dividend history here>>>
Check Fastenal’s dividend history here>>>
With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -3.17% in 2025 Q2 vs. the S&P 500 index’s +10.94% gain and the Dividend Aristocrats ETF’s (NOBL) -0.09% return. Year-to-date (through June 30th), the portfolio returned +2.38% vs. +2.18% gain for the Dividend Aristocrat ETF.
For the full-year 2024, the portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL.
The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stock MasTec Delivers Solid Returns
MasTec, Inc. (MTZ - Free Report) , from the Zacks Top 10 Stocks for 2025, has jumped 33.5% year to date compared with the S&P 500 Index’s 10.1% increase.
The Top 10 portfolio returned +11.8% this year (through the end of June 2025) vs. +6.2% for the S&P 500 index and +4.8% for the equal-weight version of the index.
The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index. The portfolio had returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.
Since 2012, the Top 10 portfolio has produced a cumulative return of +2,220.4% through the end of July 2025 vs. +517.8% for the S&P 500 index and +378% for the equal-weight version of the index. The portfolio has produced an average return of +26.1% in the period 2012 through July 31, 2025, vs. +14.4% for the S&P 500 index and +12.2% for the equal-weight version of the index.